<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01903135</url>
  </required_header>
  <id_info>
    <org_study_id>13-AGIR-02</org_study_id>
    <secondary_id>2013-A00744-41</secondary_id>
    <nct_id>NCT01903135</nct_id>
  </id_info>
  <brief_title>Prevalence of Obesity Hypoventilation Syndrome</brief_title>
  <acronym>BIO-OHS</acronym>
  <official_title>Prevalence of Obesity Hypoventilation Syndrome in Subjects With Obesity Referred to Clinical (Medical Analysis) Laboratories for Regular Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGIR à Dom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGIR à Dom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale of the &quot;BIO-OHS&quot; study (Prevalence of Obesity Hypoventilation Syndrome):

      The overall prevalence of Obesity Hypoventilation Syndrome (OHS) has never been directly
      assessed in the general population. Actually, this prevalence has been assessed in patients
      referred to sleep clinics with a potential diagnosis of sleep-disordered breathing or in
      patients already diagnosed with sleep apnea. The purpose of this study is to determine the
      prevalence of Obesity Hypoventilation syndrome in obese patients referred to clinical
      laboratories for regular follow-up medical analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No additional description
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Obesity Hypoventilation Syndrome (OHS) in obese subjects referred to clinical laboratories for regular blood test analysis.</measure>
    <time_frame>From date of inclusion until the end of the study currently planned (up to 2 years)</time_frame>
    <description>OHS prevalence, validated by arterial blood gases analysis, will be assessed by the percentage of patients with OHS among all patients included in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of plasmatic [HCO3-] to detect OHS</measure>
    <time_frame>From date of inclusion to the end of the study currently planned (2 years)</time_frame>
    <description>A ROC curve will determine if the threshold of 27 mmol/L has the best diagnostic value.
Decision trees will show if the diagnostic value of plasmatic [HCO3-]could be optimized by a combination with other clinical parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of metabolic and cardiovascular comorbidities in patients with OHS</measure>
    <time_frame>From date of inclusion to the end of the study currently planned (2 years)</time_frame>
    <description>Prevalence will be estimated by the percentage and the confidence interval. Prevalences of metabolic and cardiovascular comorbidities among patients with OHS and without OHS will be compared by a KHI-2 test or Fisher Exact depends on the theorical number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine which medical specialties referred patients with OHS to clinical labs</measure>
    <time_frame>From date of inclusion to the end of the study currently planned (2 years)</time_frame>
    <description>estimated by percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious health events at 1 and 2-year follow-up</measure>
    <time_frame>From time of OHS diagnostic to 1 and 2-year follow-up</time_frame>
    <description>Cardiovascular, metabolic and respiratory events (measured by percentages in OHS group and non-OHS group) will be compared by logistic regressions.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1004</enrollment>
  <condition>Obesity Hypoventilation Syndrome</condition>
  <arm_group>
    <arm_group_label>[HCO3-] &gt;= 27 mmol/L (Group 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All obese patients with plasmatic[HCO3-] &gt;= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[HCO3-]&lt; 27mmol/L+pneumologist (Group 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Among obese patients with serum [HCO3-]&lt; 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[HCO3-]&lt; 27 mmol/L (Group 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Obese patients with a [HCO3-]&lt;27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood test analysis in the clinical labs</intervention_name>
    <description>for specific measurement of plasmatic bicarbonate</description>
    <arm_group_label>[HCO3-] &gt;= 27 mmol/L (Group 1)</arm_group_label>
    <arm_group_label>[HCO3-]&lt; 27mmol/L+pneumologist (Group 2)</arm_group_label>
    <arm_group_label>[HCO3-]&lt; 27 mmol/L (Group 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pneumologist consult to establish the diagnosis of OHS</intervention_name>
    <description>complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.
Medical history, previous treatments.</description>
    <arm_group_label>[HCO3-] &gt;= 27 mmol/L (Group 1)</arm_group_label>
    <arm_group_label>[HCO3-]&lt; 27mmol/L+pneumologist (Group 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old ans more

          -  BMI over 30 kg/M2

          -  Stable state (respiratory, metabolic and cardio-vascular) for the last 2 months

          -  Addressed to a clinical labs for a blood check-up whatever the prescription

        Exclusion Criteria:

          -  No social security

          -  Non cooperative patient, as judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis Pepin, Pr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabinet de Pneumologie Grenoble SUD</name>
      <address>
        <city>Echirolles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire MEDIBIO Les Cedres</name>
      <address>
        <city>Echirolles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Michallon, Laboratoire EFCR et Sommeil</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet de Pneumologie Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire d'analyses medicales de Thuir</name>
      <address>
        <city>Thuir</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2013</study_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity Hypoventilation Syndrome</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Bicarbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

